<DOC>
	<DOCNO>NCT01796782</DOCNO>
	<brief_summary>Primary End Point : - To compare overall survival ( OS ) use QYHJ Granules Xeloda second therapy patient metastatic pancreatic cancer . Secondary End Points : - Compare clinical efficacy measure include PFS , tumor response , change quality life ( QOL ) two group . - Examine feasibility assess side effect treatment use QYHJ Granules patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>QYHJ Granules Versus Xeloda Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically/cytologically confirm metastatic pancreatic adenocarcinoma . Patients fail prior chemotherapy without Xeloda . Adjuvant chemotherapy contain Xeloda 6 month recruitment include . Patients n't take QYHJ Granules . Prior exposure Traditional Chinese Medicine base QYHJ Formula allow provide least one week washout time give prior initiation experimental treatment . ECOG performance status 0 , 1 2 . Measurable disease RECIST criterion must present . Bone scan abnormality alone accept measurable disease . Lytic lesion see plain radiographs accept measurable disease evaluate conjunction bone scan abnormality . Pure blastic bone metastasis accept measurable disease . Pleural peritoneal effusion accept measurable disease . Irradiated lesion consider measurable . Patients must pregnant . Serum betaHCG check premenopausal patient . Patients must adequate organ function reflect laboratory criterion : neutrophil count ≥ 1.5×109 /L , platelet count ≥ 100 x 109/L , hemoglobin ≥ 85 g/L , Serum creatinine &lt; 2.0 mg/dL , Bilirubin &lt; 1.5 mg/dL , ALT &lt; 3 x normal , albumin &gt; 30g/L . Age ≥ 18 . Prior local therapy , e.g. , TACE radiation , allow provide least 4 week washout time give . Concomitant bisphosphonates allow patient bone metastasis . Patients jaundice must biliary drainage decompression operation recruitment . Ability understand willingness sign write informed consent . Subjects life expectancy least 3 month . ECOG performance status 3 4 . Known central nervous system involvement leptomeningeal disease . Previous Xelodabased chemotherapy （except usage Adjuvant chemotherapy 6 month recruitment） . Prior treatment QYHJ Granules . Other serious illness condition include cardiac disease include congestive heart failure ( New York Heart Association Classification III IV ) , unstable angina , myocardial infarction within past six month , severe arrhythmia . Concurrent infection require intravenous antibiotic , active HIV infection/HIV disease , psychiatric disorder , drug abuse . Known allergy QYHJ Xeloda . Pregnant lactate female . Serum pregnancy test assess within 7 day prior study treatment start , within 14 day confirmatory urine pregnancy test within 7 day prior study treatment start . Men woman childbearing potential use effective mean contraception . Known nonadenocarcinoma pathological type . Other primary tumour ( include primary brain tumour ) within last 5 year prior enrollment , except adequately treat carcinoma situ cervix basal cell skin cancer . Inability take oral medication , prior surgical procedure affect absorption unwilling take Traditional Chinese Medicine . Patiens suffer diarrhea . Subjects poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>